Positions

Overview

  • Rebecca Arend, MD is Assistant Professor and an Associate Scientist at the UAB Comprehensive Cancer Center Experimental Therapeutics Program. She completed her undergraduate degree and her residency at Columbia Presbyterian in New York, NY and completed her fellowship at UAB. Prior to fellowship, she did research in hormonal and molecular pathways associated with uterine carcinosarcoma. During her fellowship in Gyn Oncology at UAB, she received an AAOGF/ABOG Young Investigator Fellowship grant that currently supports her own lab with 75% protected research time. Her on-going projects include personalized medicine, targeting the Wnt pathway, and immunotherapy in ovarian cancer patients. She is getting her Master’s degree (MSPH) in Clinical and Translational Research and serves as the chair of UAB’s Tissue Committee and as the co-chair of the Gynecologic Oncology Disease Oriented Working Group (DOWG) and the Precision Oncology Working Group (POWG). She is a member of multiple professional societies and committees both regionally and nationally. She has authored numerous publications and been highly recognized for outstanding presentations.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growthCancer Immunology, Immunotherapy.  68:175-188. 2019
    2019 Overcoming immune suppression with epigenetic modification in ovarian cancerJournal of Laboratory and Clinical Medicine.  204:31-38. 2019
    2018 The antitumor effects of entinostat in ovarian cancer require adaptive immunityCancer.  124:4657-4666. 2018
    2018 Revisiting entinostat as an immune-potentiating adjuvantOncotarget.  9:37278-37279. 2018
    2018 Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing ParadigmOncologist.  23:1533-1545. 2018
    2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancerCancer Letters.  436:75-86. 2018
    2018 Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national surveyGynecologic Oncology.  150:494-500. 2018
    2018 Endometrial cancer: Molecular markers and management of advanced stage diseaseGynecologic Oncology.  150:569-580. 2018
    2018 Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: A randomized, controlled trialNutrients.  10. 2018
    2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinomaCell Growth and Differentiation.  16:813-824. 2018
    2018 Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466Oncotarget.  9:19459-19459. 2018
    2018 Histone methyltransferase ezh2: A therapeutic target for ovarian cancerMolecular Cancer Therapeutics.  17:591-602. 2018
    2018 Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcomaCancer Medicine.  7:616-625. 2018
    2018 A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancerJournal of Nutrition.  148:1253-1260. 2018
    2017 Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewGynecologic Oncology Reports.  20:81-86. 2017
    2017 B7-H3-targeted 212 Pb radioimmunotherapy of ovarian cancer in preclinical modelsNuclear Medicine and Biology.  47:23-30. 2017
    2017 Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growthOncotarget.  8:44159-44170. 2017
    2017 Implementation and utilization of the molecular tumor board to guide precision medicineOncotarget.  8:57845-57854. 2017
    2017 Uterine carcinosarcomas: Clinical, histopathologic and immunohistochemical characteristicsInternational Journal of Gynecologic Pathology.  36:412-419. 2017
    2016 Ovarian cancer and the immune system — The role of targeted therapiesGynecologic Oncology.  142:349-356. 2016
    2016 The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotypeCancer Research.  76:3978-3988. 2016
    2016 Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974Laboratory Investigation.  96:249-259. 2016
    2016 Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A reviewGynecologic Oncology.  143:674-683. 2016
    2016 Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancerOncotarget.  7:86803-86815. 2016
    2015 PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysisGynecologic Oncology.  139:59-62. 2015
    2015 Niclosamide analogs for treatment of ovarian cancerInternational Journal of Gynecological Cancer.  25:1377-1385. 2015
    2014 Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?World Journal of Stem Cells.  6:441-447. 2014
    2014 Multi-targeted therapy of cancer by niclosamide: A new application for an old drugCancer Letters.  349:8-14. 2014
    2014 Effect of niclosamide on basal-like breast cancersMolecular Cancer Therapeutics.  13:800-811. 2014
    2014 Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancerGynecologic Oncology.  134:112-120. 2014
    2014 Radical surgical cytoreduction in the treatment of ovarian carcinosarcomaGynecologic Oncology.  133:234-237. 2014
    2013 The Wnt/β-catenin pathway in ovarian cancer: A reviewGynecologic Oncology.  131:772-779. 2013
    2013 Folate and folate receptor alpha antagonists mechanism of action in ovarian cancerGynecologic Oncology.  131:493-498. 2013
    2012 Failure to rescue as a source of variation in hospital mortality for ovarian cancerJournal of Clinical Oncology.  30:3976-3982. 2012
    2011 Uterine carcinosarcomaCurrent Opinion in Oncology.  23:531-536. 2011
    2010 Long-term outcome and natural history of uterine adenosarcomasGynecologic Oncology.  119:305-308. 2010
    2010 Co-expression of GPR30 and ERβ and their association with disease progression in uterine carcinosarcomaAmerican Journal of Obstetrics and Gynecology.  203:242.e1-242.e5. 2010
    2010 Fertility preservation in ovarian cancerTherapy.  7:257-267. 2010
    2009 Extragenital adenosarcoma: A case report, review of the literature, and management discussionGynecologic Oncology.  115:472-475. 2009
    2009 Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcomaAmerican Journal of Obstetrics and Gynecology.  200:457.e1-457.e5. 2009

    Research Overview

  • Clinical Trials
    Translational Research
    Basic Science Research
    Immunotherapy
    Genomics
    Biomarker Discovery
    Early Detection
    Molecular Targeted Therapy
    Personalized Medicine
    Hereditary Ovarian Cancer Syndrome
    Carcinosarcoma
  • Education And Training

  • Doctor of Medicine, Yeshiva University 2008
  • Columbia Presbyterian Medical Center, Residency 2012
  • Full Name

  • Rebecca Arend